Coherus Biosciences | CHRS - Debt


Coherus Biosciences reported $294.92M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amarin USD 0 0 Mar/2025
Amgen USD 54.6B 17M Dec/2025
Baxter International USD 9.78B 68M Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Fujifilm JPY 922.82B 236.91B Sep/2025
Gilead Sciences USD 24.94B 5M Dec/2025
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Merck USD 49.34B 7.97B Dec/2025
Myriad Genetics USD 59.3M 19.7M Mar/2025
Pacira USD 367.66M 4.53M Mar/2026
Perrigo USD 3.64B 4.5M Dec/2025
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Teva Pharmaceutical Industries USD 17.09B 21M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026
Xencor USD 187.75M 118.48M Dec/2025
Zoetis USD 9.24B 1.96B Dec/2025